Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Bjoern Papke et al.|Cancer Research|2022Cited by 160
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor EvolutionGrace R. Anderson, Kris C. Wood, Peter Winter et al.|Cell Reports|2017Cited by 86
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Ryan B. Corcoran, Eric Van Cutsem, Thierry André et al.|Annals of Oncology|2016Cited by 46
LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)Eric Van Cutsem, Ryan B. Corcoran, Chloé E. Atreya et al.|Annals of Oncology|2015Cited by 23
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Mareen Lüthen, Sehrish Javaid, Jennifer E. Klomp et al.|UNC Libraries|2024Cited by 12